This study aims to examine and compare changes in quality of life after two common treatments for prostate cancer (PC), radical prostatectomy (RP) and radiation therapy (RT). Patients newly diagnosed with localized PC, scheduled to receive RP (n ¼ 68) or RT (n ¼ 66), completed three cancer/PC-specific psychometric instruments and three PC-specific utility instruments before treatment, and 2 and 12 months after treatment. We assessed the magnitude and time course of changes in psychometric and utility measures, and differences between treatments. The results showed that RP was associated with significant urinary and sexual dysfunction; RT caused bowel problems. Fatigue and pain were common to both. RP patients reported more problems with physical, role and social function. Utilities decreased significantly after both treatments. Effects were most severe 2 months post treatment, and then showed some recovery, but many endured for 1 year. After 1 year, 30-60% of patients had utility scores that were clinically significantly worse than at baseline. Secondary androgen deprivation therapy also significantly decreased psychometric and utility measures of quality of life. Many adverse symptoms reported 2 months after RP and RT endure for 1 year. Despite different symptom profiles, RP and RT result in similar utility decrements.
Introduction
Health-related quality of life is an important consideration in treatment decisions for localized prostate cancer (PC). 1, 2 The most common curative treatments, radical prostatectomy (RP) and external beam radiation therapy (RT) have significant effects on quality of life. Most studies report that RP impairs sexual function and urinary control, whereas RT affects bowel function. 1, [3] [4] [5] [6] Symptoms are most severe within approximately 3 months after treatment, and then slowly improve. 3, [7] [8] [9] Many patients continue to experience symptoms 1-2 years later. 1, 3, 4, 6, 7, 10, 11 Pain, fatigue, and physical and social function are also affected. 1, 3, 7, 8, 10 Most studies measured quality of life using psychometric instruments. Another approach uses the concept of utility. Utility is a global measure of health status, scaled between 0 (dead) and 1 (full health). 12, 13 Utility reflects not only symptoms or feelings as measured on psychometric instruments, but also patients' values or preferences for them. Utilities can be measured directly using methods such as the standard gamble and rating scale, 12, 13 or elicited indirectly using health status indexes. In these questionnaire-style instruments, patients' responses characterize their current health state, and utility weights are derived from patients or the general public. Our Patient Oriented Prostate Utility Scale (PORPUS-U) 7, 14, 15 is one such instrument. Utilities are used in cost-effectiveness analyses as a way of weighting life years to generate estimates of quality-adjusted life expectancy. They are also used in clinical studies as single, global, quantitative measures of quality of life. In this study, we consider non-preferencebased (psychometric) and preference-based (utility) measures to be two distinct approaches to health-related quality of life measurement.
Purpose
The primary objectives were to describe changes in healthrelated quality of life using psychometric and utility measures in PC patients before, 2 months after and 12 months after RP or RT, and to compare the magnitude and duration of these changes across treatments.
Methods

Study population
Patients diagnosed with clinically localized PC within the previous 6 months were recruited from outpatient clinics of urologists and radiation oncologists at the Princess Margaret Hospital, a regional cancer center in Toronto, Canada. Patients who were scheduled to receive RP, or external beam radiation therapy or brachytherapy (RT), with or without androgen deprivation therapy (ADT) were eligible for the study. Patients were excluded if they were not fluent in English, had a psychiatric diagnosis or cognitive impairment recorded on the clinic chart, or had earlier treatment for PC.
Ethics and consent
The study was approved by the ethics review committee of the University Health Network. All patients gave written informed consent before participation.
Measures of health-related quality of life
The EORTC core questionnaire (QLQ-C30) is a cancerspecific psychometric instrument. Its scales describe physical, role, emotional, cognitive and social functioning, nine cancer-specific symptoms, and global health. 16 The Prostate Cancer Index (PC Index) assesses PC-specific symptoms: sexual, urinary, and bowel function, and associated bother. 17 The PORPUS has five broad quality-of-life items (pain, energy, emotional well-being, social support and relationship with doctor) and five PC-specific items (sexual function and desire, urinary frequency and incontinence, and bowel function). The PORPUS can be used as a psychometric instrument (PORPUS-P) with scores ranging from 0 (worst level) to 100 (best level), and as a PC-specific indirect utility instrument (PORPUS-U). 14, 15, 18 It is also used as a prompt to elicit rating scale and standard gamble utilities (PORPUS-U RS , PORPUS-U SG ).
Study design
Consenting patients attended three interviews, each approximately 1 h. Patients were interviewed after diagnosis, but before treatment (baseline), approximately 2 months after the date of RP or first fraction of RT (T2) and approximately 12 months post treatment (T3). At each interview, patients completed all instruments described above, in randomized order. Demographic and clinical information was collected by self-report and chart review at baseline and clinical information was updated at T2 and T3.
Statistical methods
We used descriptive statistics, analysis of variance and w 2 -tests to describe and compare the baseline characteristics of the treatment groups.
To examine the effects of RP and RT on health-related quality of life, we compared the post-treatment scores (T2 and T3) to the baseline scores on all instruments within each treatment group. We used a repeated measures mixed model with 'time' (baseline, T2 and T3) as a withinsubjects factor, and conducted these analyses for each treatment. Using this model, we compared mean scores between baseline and T2, and between baseline and T3.
Second, we examined differences in the magnitude and duration of the effects of RP and RT. For these analyses, treatment was a fixed between-subjects effect, time (baseline, T2 and T3) was a within-subjects effect and the dependent variables were the quality-of-life measures. We evaluated whether changes in mean scores over time were different for RP and RT by inspecting the treatment by time interactions.
Almost 60% of the RT patients, and 7% of the RP patients received neo-adjuvant or adjuvant ADT. We compared baseline scores for patients who had and had not received ADT before baseline. As patients who received ADT were older and had more comorbidity than those who did not, and as age and comorbidity may be associated with health-related quality of life, 15 we included these variables as covariates when comparing baseline scores. We also analyzed the effects of initiating ADT concurrently with the primary treatment within the RT group (no RP patients started new ADT after baseline). For this analysis, ADT was a between-subjects effect with three categories (started new ADT, continuing ADT and no ADT), and the dependent variables were change scores (T2-baseline) on the psychometric and utility measures.
To complement these comparisons of mean scores, we also examined the proportions of patients whose posttreatment utilities and PC Index function scores were no worse than baseline. The post-treatment score was no worse than baseline if it was better than or less than one-half a baseline standard deviation below his baseline score for that scale, a minimally important difference. 19 The average baseline standard deviation for the standard gamble, rating scale and PORPUS-U was 0.08, and the average baseline standard deviation for the PC Index function scales was 17.8. Therefore, 0.04 and 9.0 were the minimally important differences for the PORPUS utilities and PC Index, respectively. These criteria are also in agreement with the findings that the minimally important difference is about 5-10% of an instrument's range. 20 Two-sided P-values p0.05 were considered significant. SAS version 9.1 21 (SAS, Cary, NC, USA) was used for all analyses.
Results
Patients
A total of 305 newly diagnosed patients were invited to participate, and 180 (59%) consented. Among consenting patients, 134 (72.4%) completed all three interviews. Reasons for withdrawal included change of residence or inability to return to the clinic (n ¼ 12), health problems (n ¼ 4), lack of time or interest (n ¼ 8), loss of contact (n ¼ 17), poor language skills (n ¼ 4) and death (n ¼ 1).
We tried to schedule interviews according to the study protocol, but accommodated patients' appointments and travel arrangements. On average, baseline was 21 days
Health-related quality of life in PC patients MD Krahn et al before treatment (range ¼ 0-60). T2 was an average of 70 days after RP or the start of RT and 79% of visits were ±30 days of the target of 60 days. T3 was an average of 348 days after treatment, and 48% of visits were ± 30 days of the target of 365 days. Table 1 shows the characteristics of the patients who completed the study; 68 (50.7%) received RP and 66 (49.3%) received RT. RP patients were significantly younger than RT patients, had fewer comorbidities and less advanced disease (all Po0.05). ADT was part of the treatment plan for 39 (59%) of the patients scheduled to receive RT, whereas only 5 (7%) of the RP patients received ADT (Po0.001).
Effects of RP and RT
After treatment (T2), patients in the RP group experienced significant negative changes in the QLQ-C30 function scales, global health, pain and fatigue ( Table 2) . By 12 months (T3), only role function and pain remained significantly worse than baseline. Emotional function, however, improved at T2 and T3.
The RT patients experienced significant increases in pain, fatigue and diarrhea at T2. Pain and fatigue remained significantly increased after 1 year.
Sexual, urinary and bowel function, and their associated bother scores, significantly worsened after both treatments (Table 2 ). Sexual and urinary effects endured for 1 year after RP. The mean sexual bother score was even lower at T3 than at T2, despite some recovery of sexual function. By 1 year after RT, mean scores on bowel function and bother partially recovered to baseline levels.
The PORPUS-P scores showed a pattern similar to the PC Index scores in both treatment groups, decreasing significantly at T2 and only partially recovering at T3.
Most of the PORPUS utility scores reflected these changes (Table 2 ). In the RP patients, PORPUS-U, rating scale and standard gamble utilities significantly decreased from baseline to T2 and then increased at T3, but remained below baseline. Similar changes in utilities were observed after RT but by T3 the mean rating scale utility was not significantly different from baseline.
Differences in changes over time between treatments
There were few differences between RP and RT in changes in the QLQ-C30 scales (Table 3) . At T2, the decline in physical function and the improvement in emotional function were significantly greater among RP patients. The only symptom that was more affected by RT than RP was diarrhea at T2. Health-related quality of life in PC patients MD Krahn et al
The detrimental effects of RP on sexual and urinary function were significantly greater than those of RT at both post-treatment times (Table 3) . On the other hand, RT impaired bowel function significantly more than RP, but only at T2.
There were no significant differences between treatments in changes in the standard gamble or PORPUS-U. The mean decreases in the PORPUS-P and rating scale at T2 were greater in the RP patients, but the differences between baseline and T3 were similar for the two groups (Table 3) .
Effects of ADT ADT before baseline. A total of 35 patients (5 RP and 30 RT) received ADT before their baseline assessment. Patients who received ADT were older (mean (s.d.) ages ¼ 67.8 (6.4) and 62.7 (7.2) years, Po0.001), and had slightly more comorbidities (mean ¼ 0.77 vs 0.53, P ¼ 0.10). In a model with adjustment for age and number of comorbid conditions, patients who received ADT had significantly worse baseline scores on social function, global health, financial problems, sexual function, PORPUS-P and all utility instruments (Table 4) .
ADT concurrent with RT. A total of nine RT patients, but no RP patients, started ADT after baseline and before T2.
Therefore, their changes in health-related quality of life between baseline and T2 could be related to RT, ADT or both. A total of 30 patients were already on ADT from baseline (the 'continuing ADT' group), and therefore experiencing its effects (see above). The remaining 27 RT patients never had ADT. We compared the changes in quality of life scores between these three groups of RT patients using a mixed models analysis in which the reference group was the 'no ADT' patients. Compared with the 'no ADT' patients, the patients who received ADT after baseline had significantly larger increases in financial problems, and greater reductions in standard gamble utilities, from baseline to T2 (Table 5 ). The effect of ADT on sexual functioning was of borderline significance (P ¼ 0.07), but differences between groups are apparent. Global health and PORPUS-P scores were somewhat reduced when ADT was started after baseline (Pp0.10) ( Table 5 ). ADT did not significantly affect the other measures (all PX0.13). The changes from baseline to T2 for the 'continuing ADT' and 'no ADT' groups were not significantly different.
Minimally important differences from baseline
We calculated the percentages of patients in each treatment group who did not report worse PORPUS Health-related quality of life in PC patients MD Krahn et al utilities and PC Index scores at T2 and T3 than at baseline, using the criteria described above (Statistical Methods). At T2, only 15-20% of the RP patients were no worse on baseline sexual and urinary function, compared with 50-65% of the RT patients (Figure 1 , both Po0.0001). On the other hand, at T2, only 36% of the RT patients were no worse than baseline on bowel function, compared with 66% of the RP patients (Po0.001). The rating scale was the only PORPUS utility for which the percentages of patients who were no worse than baseline were different (Figure 1 top) ; at T2, 58% of the RT patients and 35% of the RP patients were no worse than baseline (Po0.01). By T3, more patients had scores that were not worse than baseline (Figure 1 bottom) . However, bowel function was the only measure on which more than 65% of the RP patients were no worse than baseline. The RT patients showed a better pattern; at least 65% were no worse than baseline on the PORPUS-U, and PC Index urine and bowel function.
Discussion
Patients' health-related quality of life does not return to pre-treatment by 1 year
The most important contribution that our study makes to the quality-of-life literature in PC is the description of significant and long-lasting changes in utility after RP Health-related quality of life in PC patients MD Krahn et al and RT. Although the effects of treatment on symptoms and functioning that were observed in our study have been described previously, our data suggest that treatments have a clinically meaningful effect on utility as well. At 2 months after treatment, mean decrements from baseline on PORPUS utilities ranged from 0.04 to 0.11. A minimally important difference in an instrument's score is considered to be one-half of the standard deviation of the score at baseline, or 5-10% of an instrument's range 19, 20 , therefore these decrements represent meaningful change. Even 1 year after treatment, mean PORPUS utility decrements from baseline ranged from 0.02 to 0.06, and 30-60% of patients had scores that were worse than at baseline by a clinically significant amount. If patients eventually adapted to their post-treatment symptoms, one would expect that by 1 year post treatment, rating scale and standard gamble utilities would be no different than they were at baseline. However, the mean decreases from baseline in standard gamble utilities are 0.05 at T3 and 0.05-0.08 at T2. This indicates that patients were willing to take a 5% higher risk of death to achieve full health 1 year after RP or RT than they were before PC treatment.
Treatments produce different symptoms but the same effect on utility at 12 months
The effects of RP included declines in physical, social and role function, also reported elsewhere 3, 8, 10 In contrast, the RT patients reported no significant changes in function. Both treatments resulted in significant increases in pain and fatigue, which lasted up to 1 year.
Despite their different effects on functioning and symptoms, RP and RT resulted in similar utility decrements on most measures at 1 year. The mean change relative to baseline was greater for RP patients for most utility measures, but differences between treatments reached statistical significance only on the rating scale. In a recent meta-analysis, we found that bowel and urinary dysfunction were associated with greater utility decrements than sexual dysfunction. 22 This study indicates that sexual and urinary dysfunction after RP may have a similar effect on global quality of life (utility) as the bowel problems after RT. Fatigue and pain may Health-related quality of life in PC patients MD Krahn et al have also contributed to changes in utility after both treatments.
Importance of baseline measures
Similar to some recent studies, 3,9 our study included baseline measures. This allows each subject to serve as his own control, and also provides information about pre-treatment function. For example, the low posttreatment sexual function scores must be considered in light of the fact that at baseline, only 31% of the RP patients and 11% of the RT patients were potent (PC Index sexual function scores X80
23
). Some of the symptoms experienced by PC patients after RP or RT are also present in older men in the general population. A 2003 survey of 4539 Canadian men aged 40 years and older and involved in a heterosexual relationship found that 34% of respondents had erectile dysfunction. 24 A Canada-wide telephone survey conducted in 2002 found that 49% of the 275 men aged 41 and older who were interviewed reported at least one urinary symptom, including nocturia, urgency, frequency or incontinence. 25 Neglecting to measure baseline function in these areas may overestimate the effects of RP and RT. However, our study showed that even poor function at baseline can worsen after treatment.
ADT affects quality of life in patients with localized PC Neo-adjuvant or adjuvant ADT is often recommended for patients with locally advanced or high risk PC receiving RP or RT. 26, 27 The potential consequences of ADT include osteoporosis, increased fat mass, anemia and perhaps cognitive decline, as well as hot flashes and sexual dysfunction. 28 Other studies on the effects of PC treatments noted that patients received secondary ADT, 3, 29, 30 but only one examined its effects on quality of life. 30 In that cross-sectional study, ADT decreased the role and sexual function among patients who received RT. However, it was not clear whether ADT affected global quality of life. Our study found that it did; ADT had significant effects on utility at baseline, when 26% of the patients had started ADT. Only nine patients initiated ADT after the baseline interview, but even with this small number, negative ADT effects were found on the standard gamble.
Limitations
Our study has some limitations. Patients were recruited from one center and were quite highly educated, limiting the generalizability of our findings. Treatments were not randomized, and treatment groups differed significantly in age, comorbidity and disease stage. We accounted for this by comparing within-subject changes before and after treatment, therefore each patient served as his own control. When comparing patients with and without prebaseline ADT; we included age and comorbidity as covariates, and presented scores adjusted for these variables. We did not examine interactions between treatment and demographic or clinical variables to determine whether, for example, older patients experienced more or less post-treatment change than younger ones. This was not the focus of our study. A longer follow-up period would have added to the study. However, other studies with 2-year follow-ups found little change in measures of quality of life after 1 year.
3,29
Conclusions
Health-related quality of life is an important consideration in treatment decision-making for localized PC. Most studies used psychometric instruments to measure symptoms and functioning, and the need to examine overall quality of life has been noted. 29 Our study addressed this need by including utility measures. Utilities are unique in that they include the concept of patient preference. RP and RT have clinically significant, long-lasting and different side effect profiles. The decrements on most utility measures are clinically significant and they are similar after both treatments, indicating that RP and RT patients have similar quality of life 1 year after treatment. The effect of ADT deserves further study. The potential survival gains associated with ADT 27 must be weighed against the potential negative effect on health-related quality of life.
